Issues related to development of new antiseizure treatments

Karen S. Wilcox, Tracy Dixon-Salazar, Graeme J. Sills, Elinor Ben-Menachem, H. Steve White, Roger J. Porter, Marc A. Dichter, Solomon L. Moshe, Jeffrey L. Noebels, Michael D. Privitera, Michael A. Rogawski

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers. Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)24-34
Number of pages11
JournalEpilepsia
Volume54
Issue numberSUPPL.4
DOIs
StatePublished - Aug 2013

Fingerprint

Epilepsy
Seizures
National Institute of Neurological Disorders and Stroke
Group Processes
Drug Industry
Anticonvulsants
Animal Models
Research Personnel
Pediatrics
Therapeutics

Keywords

  • Animal models of epilepsy
  • Antiseizure drug
  • Pharmacoresistant epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Wilcox, K. S., Dixon-Salazar, T., Sills, G. J., Ben-Menachem, E., White, H. S., Porter, R. J., ... Rogawski, M. A. (2013). Issues related to development of new antiseizure treatments. Epilepsia, 54(SUPPL.4), 24-34. https://doi.org/10.1111/epi.12296

Issues related to development of new antiseizure treatments. / Wilcox, Karen S.; Dixon-Salazar, Tracy; Sills, Graeme J.; Ben-Menachem, Elinor; White, H. Steve; Porter, Roger J.; Dichter, Marc A.; Moshe, Solomon L.; Noebels, Jeffrey L.; Privitera, Michael D.; Rogawski, Michael A.

In: Epilepsia, Vol. 54, No. SUPPL.4, 08.2013, p. 24-34.

Research output: Contribution to journalArticle

Wilcox, KS, Dixon-Salazar, T, Sills, GJ, Ben-Menachem, E, White, HS, Porter, RJ, Dichter, MA, Moshe, SL, Noebels, JL, Privitera, MD & Rogawski, MA 2013, 'Issues related to development of new antiseizure treatments', Epilepsia, vol. 54, no. SUPPL.4, pp. 24-34. https://doi.org/10.1111/epi.12296
Wilcox KS, Dixon-Salazar T, Sills GJ, Ben-Menachem E, White HS, Porter RJ et al. Issues related to development of new antiseizure treatments. Epilepsia. 2013 Aug;54(SUPPL.4):24-34. https://doi.org/10.1111/epi.12296
Wilcox, Karen S. ; Dixon-Salazar, Tracy ; Sills, Graeme J. ; Ben-Menachem, Elinor ; White, H. Steve ; Porter, Roger J. ; Dichter, Marc A. ; Moshe, Solomon L. ; Noebels, Jeffrey L. ; Privitera, Michael D. ; Rogawski, Michael A. / Issues related to development of new antiseizure treatments. In: Epilepsia. 2013 ; Vol. 54, No. SUPPL.4. pp. 24-34.
@article{1b05e1cc2b134d569ddae7067d09abe3,
title = "Issues related to development of new antiseizure treatments",
abstract = "This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers. Wiley Periodicals, Inc.",
keywords = "Animal models of epilepsy, Antiseizure drug, Pharmacoresistant epilepsy",
author = "Wilcox, {Karen S.} and Tracy Dixon-Salazar and Sills, {Graeme J.} and Elinor Ben-Menachem and White, {H. Steve} and Porter, {Roger J.} and Dichter, {Marc A.} and Moshe, {Solomon L.} and Noebels, {Jeffrey L.} and Privitera, {Michael D.} and Rogawski, {Michael A.}",
year = "2013",
month = "8",
doi = "10.1111/epi.12296",
language = "English (US)",
volume = "54",
pages = "24--34",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "SUPPL.4",

}

TY - JOUR

T1 - Issues related to development of new antiseizure treatments

AU - Wilcox, Karen S.

AU - Dixon-Salazar, Tracy

AU - Sills, Graeme J.

AU - Ben-Menachem, Elinor

AU - White, H. Steve

AU - Porter, Roger J.

AU - Dichter, Marc A.

AU - Moshe, Solomon L.

AU - Noebels, Jeffrey L.

AU - Privitera, Michael D.

AU - Rogawski, Michael A.

PY - 2013/8

Y1 - 2013/8

N2 - This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers. Wiley Periodicals, Inc.

AB - This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers. Wiley Periodicals, Inc.

KW - Animal models of epilepsy

KW - Antiseizure drug

KW - Pharmacoresistant epilepsy

UR - http://www.scopus.com/inward/record.url?scp=84891676185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891676185&partnerID=8YFLogxK

U2 - 10.1111/epi.12296

DO - 10.1111/epi.12296

M3 - Article

VL - 54

SP - 24

EP - 34

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL.4

ER -